Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 93

1.

Hypertension and Incident Cardiovascular Events Following Ibrutinib Initiation.

Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, Guha A, Rogers KA, Bhatt S, Byrd JC, Woyach JA, Awan F, Addison D.

Blood. 2019 Oct 3. pii: blood.2019000840. doi: 10.1182/blood.2019000840. [Epub ahead of print]

PMID:
31582362
2.

Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib.

Kander EM, Zhao Q, Bhat SA, Hirsch J, Byrd JC, Ooka L, Wiczer T, Woyach JA, Awan FT, Rogers KA, Wang TF.

Br J Haematol. 2019 Sep 18. doi: 10.1111/bjh.16209. [Epub ahead of print] No abstract available.

PMID:
31531846
3.

Making clinical trials work for older patients with chronic lymphocytic leukemia.

Woyach JA.

J Geriatr Oncol. 2019 Sep 13. pii: S1879-4068(19)30328-5. doi: 10.1016/j.jgo.2019.08.006. [Epub ahead of print] No abstract available.

PMID:
31526530
4.

Final analysis from RESONATE: up to 6 years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA.

Am J Hematol. 2019 Sep 11. doi: 10.1002/ajh.25638. [Epub ahead of print]

PMID:
31512258
5.

Can Combination Targeted Therapy Bring About Another Paradigm Shift in Chronic Lymphocytic Leukemia?

Woyach JA.

J Clin Oncol. 2019 Oct 20;37(30):2711-2713. doi: 10.1200/JCO.19.01718. Epub 2019 Aug 28. No abstract available.

PMID:
31461378
6.

T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma.

Lucas F, Pennell M, Huang Y, Benson DM, Efebera YA, Chaudhry M, Hughes T, Woyach JA, Byrd JC, Zhang S, Jones D, Guan X, Burd CE, Rosko AE.

Biol Blood Marrow Transplant. 2019 Aug 21. pii: S1083-8791(19)30523-3. doi: 10.1016/j.bbmt.2019.08.009. [Epub ahead of print]

PMID:
31445183
7.

Identifying risk factors for depression and anxiety symptoms in patients with chronic lymphocytic leukemia.

Robbertz AS, Weiss DM, Awan FT, Byrd JC, Rogers KA, Woyach JA.

Support Care Cancer. 2019 Jul 22. doi: 10.1007/s00520-019-04991-y. [Epub ahead of print]

PMID:
31332513
8.

Contemporary impacts of a cancer diagnosis on survival following in-hospital cardiac arrest.

Guha A, Buck B, Biersmith M, Arora S, Yildiz V, Wei L, Awan F, Woyach J, Lopez-Mattei J, Plana-Gomez JC, Oliveira GH, Fradley MG, Addison D.

Resuscitation. 2019 Sep;142:30-37. doi: 10.1016/j.resuscitation.2019.07.005. Epub 2019 Jul 13.

PMID:
31310845
9.

Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma.

Lucas F, Rogers KA, Harrington BK, Pan A, Yu L, Breitbach J, Bundschuh R, Goettl VM, Hing ZA, Kanga P, Mantel R, Sampath D, Smith LL, Wasmuth R, White DK, Yan P, Byrd JC, Lapalombella R, Woyach JA.

Clin Cancer Res. 2019 Jul 11. doi: 10.1158/1078-0432.CCR-19-0273. [Epub ahead of print]

PMID:
31296529
10.

Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia.

Giacopelli B, Zhao Q, Ruppert AS, Agyeman A, Weigel C, Wu YZ, Gerber MM, Rabe KG, Larson MC, Lu J, Blachly JS, Rogers KA, Wierda WG, Brown JR, Rai KR, Keating M, Rassenti LZ, Kipps TJ, Zenz T, Shanafelt TD, Kay NE, Abruzzo LV, Coombes KR, Woyach JA, Byrd JC, Oakes CC.

Blood. 2019 Aug 22;134(8):688-698. doi: 10.1182/blood.2019000490. Epub 2019 Jul 10.

11.

Arti Hurria, M.D.: A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology.

Alliance Cancer in the Older Adult Committee, Adjei A, Buckner JC, Cathcart-Rake E, Chen H, Cohen HJ, Dao D, De Luca JE, Feliciano J, Freedman RA, Goldberg RM, Hopkins J, Hubbard J, Jatoi A, Karuturi M, Kemeny M, Kimmick GG, Klepin HD, Krok-Schoen JL, Lafky JM, Le-Rademacher JG, Li D, Lichtman SM, Maggiore R, Mandelblatt J, Morrison VA, Muss HB, Ojelabi MO, Sedrak MS, Subbiah N, Sun V, Tuttle S, VanderWalde N, Wildes T, Wong ML, Woyach J.

J Geriatr Oncol. 2019 Jun 11. pii: S1879-4068(19)30158-4. doi: 10.1016/j.jgo.2019.05.011. [Epub ahead of print] Review. No abstract available.

PMID:
31201095
12.

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.

Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Woyach J, Bibikova E, Charuworn P, Frigault MM, Hamdy A, Izumi R, Linghu B, Patel P, Wang MH, Byrd JC.

Blood Adv. 2019 May 14;3(9):1553-1562. doi: 10.1182/bloodadvances.2018030007.

13.

Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies.

Rogers KA, Mousa L, Zhao Q, Bhat SA, Byrd JC, El Boghdadly Z, Guerrero T, Levine LB, Lucas F, Shindiapina P, Sigmund AM, Sullivan M, Wiczer TE, Woyach JA, Awan FT.

Leukemia. 2019 Oct;33(10):2527-2530. doi: 10.1038/s41375-019-0481-1. Epub 2019 May 13. No abstract available.

PMID:
31086260
14.

Targeting BTK in CLL: Beyond Ibrutinib.

Bond DA, Woyach JA.

Curr Hematol Malig Rep. 2019 Jun;14(3):197-205. doi: 10.1007/s11899-019-00512-0. Review.

PMID:
31028669
15.

Ibrutinib Regimens in Older Patients with Untreated CLL. Reply.

Woyach JA, Ruppert AS, Mandrekar SJ.

N Engl J Med. 2019 Apr 25;380(17):1680-1681. doi: 10.1056/NEJMc1901284. No abstract available.

PMID:
31018081
16.

Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.

Lucas F, Woyach JA.

Target Oncol. 2019 Apr;14(2):125-138. doi: 10.1007/s11523-019-00635-7. Review.

PMID:
30927175
17.

Representation of Patients With Cardiovascular Disease in Pivotal Cancer Clinical Trials.

Bonsu J, Charles L, Guha A, Awan F, Woyach J, Yildiz V, Wei L, Jneid H, Addison D.

Circulation. 2019 May 28;139(22):2594-2596. doi: 10.1161/CIRCULATIONAHA.118.039180. Epub 2019 Mar 18. No abstract available.

PMID:
30882246
18.

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.

Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR.

Blood. 2019 May 9;133(19):2031-2042. doi: 10.1182/blood-2018-08-870238. Epub 2019 Mar 6.

PMID:
30842083
19.

Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia.

Ruppert AS, Yin J, Davidian M, Tsiatis AA, Byrd JC, Woyach JA, Mandrekar SJ.

Ann Oncol. 2019 Apr 1;30(4):542-550. doi: 10.1093/annonc/mdz053.

PMID:
30799502
20.

HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics.

Lai TH, Mitchell S, Wu PJ, Orwick S, Liu C, Ravikrishnan J, Woyach J, Mims A, Plunkett W, Puduvalli VK, Byrd JC, Lapalombella R, Sampath D.

Leuk Lymphoma. 2019 Sep;60(9):2308-2311. doi: 10.1080/10428194.2019.1571197. Epub 2019 Feb 18. No abstract available.

PMID:
30773117

Supplemental Content

Loading ...
Support Center